Pre-Pandemic Vaccines and

Corporate Pandemic Preparedness

An executive roundtable exploring the potential role of vaccines in corporate pandemic preparedness. The Roundtable will feature presentations on the latest developments regarding H5N1, including new pre-pandemic vaccine developments, and corporate "case study" discussions led by participants on the potential role for vaccines in corporate preparedness and countermeasure stockpiles.

Where? The Harvard Faculty Club - 20 Quincy Street, Cambridge, MA 02138

When? Wednesday, October 3, 2007 - 8:00 am - 4:00 pm

Cost: No registration fee for invited participants, courtesy of Novartis Vaccines.

Accomodation: The Inn at Harvard - 1201 Massachusetts Avenue, Cambridge, MA 02138

Reception and Dinner: The Harvard Faculty Club - 5:30 pm - 9:30 pm - October 2nd, 2007

Program:

8:00 – 8:25 am Registration and Buffet Continental Breakfast

8:30 – 8:45 am Welcome and Introduction

8:45 – 9:45 am H5N1 and Pandemic Preparedness Update
-- What is the status of H5N1 and the potential for pandemic influenza?
-- How are anti-virals and vaccines currently being used in the fight against H5N1?
-- What are the latest developments in pharmaceutical countermeasures?
-- What are the key issues surrounding pre-pandemic vaccination?

9:45 - 10:25 am Roles for Vaccines Prior to Pandemic Emergence
-- The advantages and disadvantages of pre-pandemic vaccination
-- The role of public health and government agencies in pre-pandemic vaccination
-- Does pre-pandemic vaccination “fit-in” with private countermeasure strategies and plans?

10:25-10:45 am Coffee Break

11:00-12:25 pm Corporate Perspectives on Countermeasure Stockpiles: Lessons Learned

Dr. Myles Druckman, Chief Medical Officer, International SOS -- followed by invited participant presentations on the lessons learned in planning, securing, managing, and dispensing private stockpiles of pharmaceutical countermeasures.

12:30 - 1:15 pm Buffet Lunch

1:30 - 3:00 pm Requirements for a Pre-Pandemic Vaccine

A discussion moderated by bio-era, to identify specific corporate requirements for considering pre-pandemic vaccination: the safety, efficacy, economic, ethical, social, and corporate responsibility considerations important to making such decisions.

3:00 - 3:15 pm Coffee Break

3:20 - 4:00 pm - Summary, closing comments, and adjourn

Speakers and Commentators Include:

Speakers and commentators at bio-era roundtables are drawn from the group of registered participants. Bio-era's last roundtable on pandemic preparedness (November 2006) included presentations from:

• Dr. David Nabarro, UN Senior System Coordinator for Avian and Human Influenza
• Dr. Charles Elliott, Director of Medical Affairs, Ashland Inc.
• Dr. Sol Sax, Global Chief Medical Officer, DuPont Corporation
• Mr. Birch Holt, Manager, Business Continuity, Target Corporation
• Ms. Lynn Lowry, Director, Evidence-Based Research, International Medical Corp.
• Mr. James Newcomb, Managing Director for Research, bio-era

Key questions to be answered:

• What are the potential roles for vaccines prior to pandemic emergence?
• What are the strengths and weaknesses of pre-pandemic vaccination relative to other pre-pandemic countermeasures?
• What requirements must be met prior to considering purchase of a pre-pandemic vaccine?
• When is the right time to begin pre-pandemic vaccination?

Register

Click here to apply to register for this event.

top